105 related articles for article (PubMed ID: 2355106)
1. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings.
Cutler NR; Murphy MF; Nash RJ; Prior PL; De Luna DM
J Clin Pharmacol; 1990 Jun; 30(6):556-61. PubMed ID: 2355106
[TBL] [Abstract][Full Text] [Related]
2. Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent.
Puri SK; Hsu RS; Ho I; Lassman HB
J Clin Pharmacol; 1989 Mar; 29(3):278-84. PubMed ID: 2723116
[TBL] [Abstract][Full Text] [Related]
3. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.
Cutler NR; Sramek JJ; Murphy MF; Nash RJ
Ann Pharmacother; 1992 Sep; 26(9):1118-22. PubMed ID: 1421679
[TBL] [Abstract][Full Text] [Related]
4. Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease.
Puri SK; Ho I; Hsu R; Lassman HB
J Clin Pharmacol; 1990 Oct; 30(10):948-55. PubMed ID: 2229455
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease.
Cutler NR; Sramek JJ; Murphy MF; Nash RJ
J Geriatr Psychiatry Neurol; 1992; 5(4):192-4. PubMed ID: 1418362
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
Murphy MF; Hardiman ST; Nash RJ; Huff FJ; Demkovich JJ; Dobson C; Knappe UE
Ann N Y Acad Sci; 1991; 640():253-62. PubMed ID: 1776747
[TBL] [Abstract][Full Text] [Related]
7. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
Chatellier G; Lacomblez L
BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
9. Velnacrine for Alzheimer's disease.
Birks J; Wilcock GG
Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
[TBL] [Abstract][Full Text] [Related]
10. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
12. The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent.
Puri SK; Hsu RS; Ho I; Lassman HB
J Clin Pharmacol; 1989 Oct; 29(10):956-60. PubMed ID: 2592587
[TBL] [Abstract][Full Text] [Related]
13. Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease.
Huff FJ; Antuono P; Murphy M; Beyer J; Dobson C
Ann N Y Acad Sci; 1991; 640():263-7. PubMed ID: 1776748
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease.
Ford JM; Truman CA; Wilcock GK; Roberts CJ
Clin Pharmacol Ther; 1993 Jun; 53(6):691-5. PubMed ID: 8513661
[TBL] [Abstract][Full Text] [Related]
15. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.
Summers WK; Majovski LV; Marsh GM; Tachiki K; Kling A
N Engl J Med; 1986 Nov; 315(20):1241-5. PubMed ID: 2430180
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease.
Wong WJ; Liu HC; Fuh JL; Wang SJ; Hsu LC; Wang PN; Sheng WY
Dement Geriatr Cogn Disord; 1999; 10(4):289-94. PubMed ID: 10364647
[TBL] [Abstract][Full Text] [Related]
17. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
Clipp EC; Moore MJ
Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.
Maltby N; Broe GA; Creasey H; Jorm AF; Christensen H; Brooks WS
BMJ; 1994 Apr; 308(6933):879-83. PubMed ID: 8173365
[TBL] [Abstract][Full Text] [Related]
19. Tacrine in Alzheimer's disease.
Eagger SA; Levy R; Sahakian BJ
Lancet; 1991 Apr; 337(8748):989-92. PubMed ID: 1673209
[TBL] [Abstract][Full Text] [Related]
20. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]